Tongjun Liu

Tongjun Liu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Acta Biomaterialia
Verified
Journal Article
Closed access
JLJiannan Li
Jiannan Li
XFXiangru Feng
Xiangru Feng
BLBaichun Liu
Baichun Liu
YYYingjie Yu
Yingjie Yu
LSLeming Sun
Leming Sun
XCXuesi Chen
Xuesi Chen

7 September 2017 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
JLJiannan Li
Jiannan Li
WXWeiguo Xu
Weiguo Xu
JCJinjin Chen
Jinjin Chen
DLDi Li
Di Li
KZKai Zhang
Kai Zhang
Xuesi ChenXuesi Chen
Xuesi Chen

11 April 2019 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
MFMeidan Fang
Meidan Fang
LZLili Zhong
Lili Zhong
XJXin Jin
Xin Jin
RCRanji Cui
Ranji Cui
WYWei Yang
Wei Yang
TLTongjun Liu
Tongjun Liu
A considerable body of evidence has shown that inflammation plays an important role in the process of stroke rehabilitation and development of poststroke depression (PSD). However, the specific molecular and cellular mechanisms involved remain unclear. In this review, we summarize how neuroinflammation affects stroke rehabilitation and PSD. We mainly focus on the immune/inflammatory response, involving astrocytes, microglia, monocyte-derived macrophages, cytokines (tumor necrosis factor alpha, interleukin 1), and microRNAs (microRNA-124, microRNA 133b). This review provides new insights into the effect of inflammation on the process of stroke rehabilitation and PSD and potentially offer new therapeutic targets of stroke and PSD.

1 August 2018 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
ZLZhengyang Lu
Zhengyang Lu
GZGuangxin Zhang
Guangxin Zhang
YZYifan Zhang
Yifan Zhang
PHPeiyan Hua
Peiyan Hua
MFMeidan Fang
Meidan Fang
TLTongjun Liu
Tongjun Liu

11 January 2020 in Medical Science Monitor
Verified
Journal Article
Closed access
PDF file
FLFeng Liang
Feng Liang
JLJian Li
Jian Li
KYKe Yu
Ke Yu
KZKai Zhang
Kai Zhang
TLTongjun Liu
Tongjun Liu
JLJiannan Li
Jiannan Li
A tailgut cyst is a type of benign congenital disease that mainly develops in the retro-rectal space. However, malignant transition can occur in some cases of tailgut cysts. Early and precise diagnosis, and proper treatment, are vital for pa...

1 January 2020 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
PDF file
TSTianqi Su
Tianqi Su
BYBo Yang
Bo Yang
TGTianren Gao
Tianren Gao
TLTongjun Liu
Tongjun Liu
JLJiannan Li
Jiannan Li
Pancreatic cancer is a lethal disease characterized by highly dense stroma fibrosis. Only 15–20% of patients with pancreatic cancer have resectable tumors, and only around 20% of them survive to 5 years. Traditional cancer treatments have little effect on their prognosis, and successful surgical resection combined with effective perioperative therapy is the main method for maximizing long-term survival. For this reason, chemotherapy is an adjunct treatment for resectable cancer and is the main therapy for incurable pancreatic cancer, including metastatic pancreatic adenocarcinoma. However, there are various side effects of chemotherapeutic medicine and low drug penetration because the complex tumor microenvironment limits the application of chemotherapy. As a novel strategy, polymer nanoparticles make it possible to target the tumor microenvironment, release cytotoxic agents through various responsive reactions, and thus overcome the treatment barrier. As drug carriers, polymer nanoparticles show marked advantages, such as increased drug delivery and efficiency, controlled drug release, decreased side effects, prolonged half-life, and evasion of immunogenic blockade. In this review, we discuss the factors that cause chemotherapy obstacles in pancreatic cancer, and introduce the application of polymer nanoparticles to treat pancreatic cancer.